Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × FS 069 × Clear all
NCT03199274 2026-01-02

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Thomas Jefferson University

Phase 2 Completed
104 enrolled 8 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05328167 2025-10-28

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

Thomas Jefferson University

Phase 2 Completed
16 enrolled 8 charts
Gastrointestinal

Cholangiocarcinoma

NCT02440334 2025-05-04

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

Thomas Jefferson University

Phase 2 Completed
53 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡